PBS Biotech and Rockwell Automation Enhance Cell Therapy Production Efficiency
In a significant advancement for the biotechnology sector, PBS Biotech has announced its collaboration with Rockwell Automation to integrate state-of-the-art automation into its MiniPRO™ platform, aimed at revolutionizing the development of cell therapies. This partnership is particularly timely given the pressure on Advanced Therapeutic Medicinal Products (ATMP) organizations to expedite process development while ensuring regulatory compliance and scalability.
The MiniPRO™ platform is a cutting-edge, closed bioreactor system capable of managing up to 24 independently controlled reactors simultaneously. By embedding Rockwell’s industrial automation technology, PBS Biotech is enabling a more streamlined process for developing cell therapies. One of the key components of this innovation is the use of FactoryTalk® software and the Process Library, which allows real-time process control and visibility. This integrated system enhances the ability of organizations to move from development to commercial manufacturing seamlessly.
As cell therapy continues to evolve, the challenges faced by developers are ever-increasing. Traditional methodologies often rely on low-throughput and manual processes, which can compromise efficiency and introduce risks. By adopting standardized and globally recognized automation solutions, PBS Biotech is taking crucial steps towards mitigating these issues. Sharon Harvey, the Director of Product Management and Strategy at PBS Biotech, emphasized that the integration of Rockwell technologies allows early-stage developers to gather high-quality process data in an environment that mirrors commercial manufacturing.
Notably, the Advanced Regenerative Manufacturing Institute (ARMI), a nonprofit organization dedicated to enhancing the bioeconomy, was among the early adopters of the MiniPRO™ platform. Tom Bollenbach, the Chief Technology Officer at ARMI, noted that this platform has significantly streamlined control processes that are critical for deploying larger manufacturing lines. The transition between subsystems in production lines is crucial, and with Rockwell's integration, the MiniPRO™ enhances communication between systems, facilitating greater operational coherence.
Moreover, PBS Biotech has demonstrated that the manufacturing performance on the MiniPRO is aligned with its larger Vertical-Wheel® bioreactors, thus ensuring consistency in data generation that is essential for advancing to large-scale production. This integration not only helps in maintaining control but also aids in preserving process knowledge as therapy development progresses.
As noted by Matt Weaver, Rockwell Automation’s Vice President for Global Industry - Life Sciences, maintaining a steady transition between development and manufacturing is vital to reducing risks associated with scaling up. The MiniPRO platform, by employing a widely accepted automation framework early in the developmental phase, helps ensure that clinical and commercial manufacturing requirements can be met without disruption.
In conclusion, the collaboration between PBS Biotech and Rockwell Automation represents a critical step in the industrialization of cell therapy development. By marrying advanced technology with bioreactor systems, the two companies are not only advancing scientific processes but are also paving the way for the future of biomanufacturing. This partnership is expected to set a new standard for efficiency and reliability in the development of cell-based therapies, ultimately benefiting the broader healthcare landscape by making innovative treatments more accessible and scalable.
The MiniPRO™ platform is a cutting-edge, closed bioreactor system capable of managing up to 24 independently controlled reactors simultaneously. By embedding Rockwell’s industrial automation technology, PBS Biotech is enabling a more streamlined process for developing cell therapies. One of the key components of this innovation is the use of FactoryTalk® software and the Process Library, which allows real-time process control and visibility. This integrated system enhances the ability of organizations to move from development to commercial manufacturing seamlessly.
As cell therapy continues to evolve, the challenges faced by developers are ever-increasing. Traditional methodologies often rely on low-throughput and manual processes, which can compromise efficiency and introduce risks. By adopting standardized and globally recognized automation solutions, PBS Biotech is taking crucial steps towards mitigating these issues. Sharon Harvey, the Director of Product Management and Strategy at PBS Biotech, emphasized that the integration of Rockwell technologies allows early-stage developers to gather high-quality process data in an environment that mirrors commercial manufacturing.
Notably, the Advanced Regenerative Manufacturing Institute (ARMI), a nonprofit organization dedicated to enhancing the bioeconomy, was among the early adopters of the MiniPRO™ platform. Tom Bollenbach, the Chief Technology Officer at ARMI, noted that this platform has significantly streamlined control processes that are critical for deploying larger manufacturing lines. The transition between subsystems in production lines is crucial, and with Rockwell's integration, the MiniPRO™ enhances communication between systems, facilitating greater operational coherence.
Moreover, PBS Biotech has demonstrated that the manufacturing performance on the MiniPRO is aligned with its larger Vertical-Wheel® bioreactors, thus ensuring consistency in data generation that is essential for advancing to large-scale production. This integration not only helps in maintaining control but also aids in preserving process knowledge as therapy development progresses.
As noted by Matt Weaver, Rockwell Automation’s Vice President for Global Industry - Life Sciences, maintaining a steady transition between development and manufacturing is vital to reducing risks associated with scaling up. The MiniPRO platform, by employing a widely accepted automation framework early in the developmental phase, helps ensure that clinical and commercial manufacturing requirements can be met without disruption.
In conclusion, the collaboration between PBS Biotech and Rockwell Automation represents a critical step in the industrialization of cell therapy development. By marrying advanced technology with bioreactor systems, the two companies are not only advancing scientific processes but are also paving the way for the future of biomanufacturing. This partnership is expected to set a new standard for efficiency and reliability in the development of cell-based therapies, ultimately benefiting the broader healthcare landscape by making innovative treatments more accessible and scalable.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.